SCM
BBIO icon

Silverarc Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Silverarc Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-111,000
Closed -$3.84M – 69
2025
Q1 		$3.84M Buy
+111,000
New +$3.74M 0.8% 32
2023
Q3 		– Sell
-50,000
Closed -$860K – 84
2023
Q2 		$860K Buy
50,000
+10,000
+25% +$150K 0.29% 62
2023
Q1 		$663K Buy
+40,000
New +$466K 0.3% 61
2022
Q1 		– Sell
-100,000
Closed -$1.67M – 71
2021
Q4 		$1.67M Buy
+100,000
New +$4.23M 0.75% 44

Other funds holding BBIO

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return